Peritech Pharma
Specialty Pharmaceutical Products for the Anus and Rectum
Company Overview
Snapshot
Founded in March 2012 by Eran Eilat, Peritech Pharma operates with 1–10 employees. The company secured its first commercial agreement for two over-the-counter products, PP-110 and PP-120, in 24 countries, including Brazil and other Central and South American nations, as well as the Caribbean.
Business overview
Peritech Pharma is a specialty pharmaceuticals development company focused on products for the anal/rectal area. The company's core products, PP-110 for hemorrhoids and PP-120 for anal itching, are based on known and approved active ingredients. PP-110, in particular, has demonstrated long-lasting effects in clinical trials, offering superior results in pain, itching, and bleeding compared to other treatments. Peritech Pharma serves the pharmaceutical and healthcare markets, targeting consumers and patients with its drug discovery and development efforts.
Strategic signal
In February 2018, Peritech Pharma commercialized its novel hemorrhoids treatment in 24 countries, including Brazil and other Central and South American nations, as well as the Caribbean. This strategic move signaled significant market expansion and validation of its product pipeline, demonstrating the company's ability to secure international commercial agreements and bring its specialty pharmaceutical products to a broader patient base.
Log in to access full profile ›Company Intelligence Q&A
- What is Peritech Pharma's primary focus?
- Peritech Pharma specializes in the development of specialty pharmaceutical products designed for the anal/rectal area.
- Which products has Peritech Pharma commercialized?
- Peritech Pharma has commercialized PP-110 for hemorrhoids and PP-120 for anal itching, securing a commercial agreement for these products in 24 countries in February 2018.
- What was a key finding from the clinical trial for PP-110?
- In July 2015, a pivotal trial showed that Peritech Pharma's PP-110 gel, used once daily, provided better results for pain, itching, and bleeding compared to a comparable drug used three to four times per day.
- In which regions has Peritech Pharma secured patents?
- In May 2019, Peritech Pharma was granted patents for its products in China and Russia, expanding its intellectual property protection in key international markets.
- What is the current status of Peritech Pharma?
- Peritech Pharma is currently non-active, having ceased operations in December 2023.